Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 4;18(1):74.
doi: 10.1186/s13024-023-00663-y.

Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come

John J Alam  1 , Ralph A Nixon  2   3
Affiliations

Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come

John J Alam et al. Mol Neurodegener. .

Erratum in

No abstract available

Keywords: Alzheimer’s disease; Basal forebrain; Cholinergic degeneration; Dementia with Lewy bodies; Neflamapimod; Rab5; p38α.

PubMed Disclaimer

Conflict of interest statement

JA is an employee of CervoMed, a commercial enterprise developing neflamapimod as a treatment for DLB.

Figures

Fig. 1
Fig. 1
β-CTF and/or α -synuclein induce Rab5-positive (early) endosomal swelling and dysfunction, which leads to a defect in endosome-mediated nerve growth factor (NGF) signaling. The resulting loss of trophic support provided by NGF leads to degeneration of cholinergic neurons in the basal forebrain, that downstream leads to dysfunction and eventual neurodegeneration in the cortex. Neflamapimod through inhibiting the kinase activity of p38α (an activator of Rab5) reduces Rab5 activity and reverses the endosomal pathology and cholinergic neuronal loss in the basal forebrain
See this image and copyright information in PMC

References

    1. Jiang Y, Alam JJ, Gomperts SN, Maruff P, Lemstra AW, Germann UA, et al. Preclinical and randomized clinical evaluation of the p38alpha kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration. Nat Commun. 2022;13(1):5308. doi: 10.1038/s41467-022-32944-3. - DOI - PMC - PubMed
    1. Alam J, Maruff P, Doctrow SR, Chu H-M, Conway J, Gomperts SN, et al. Association of plasma phosphorylated tau with the response to neflamapimod treatment in patients with dementia with Lewy bodies. Neurology. 2023. 10.1212/WNL.0000000000207755. Published online ahead of print. - PMC - PubMed
    1. Jiang Y, Rigoglioso A, Peterhoff CM, Pawlik M, Sato Y, Bleiwas C, et al. Partial BACE1 reduction in a Down syndrome mouse model blocks Alzheimer-related endosomal anomalies and cholinergic neurodegeneration: role of APP-CTF. Neurobiol Aging. 2016;39:90–98. doi: 10.1016/j.neurobiolaging.2015.11.013. - DOI - PMC - PubMed
    1. Jarzebowski P, Tang CS, Paulsen O, Hay YA. Impaired spatial learning and suppression of sharp wave ripples by cholinergic activation at the goal location. Elife. 2021;10. - PMC - PubMed
    1. Spencer B, Desplats PA, Overk CR, Valera-Martin E, Rissman RA, Wu C, et al. Reducing endogenous alpha-synuclein mitigates the degeneration of selective neuronal populations in an alzheimer's disease transgenic mouse model. J Neurosci. 2016;36(30):7971–7984. doi: 10.1523/JNEUROSCI.0775-16.2016. - DOI - PMC - PubMed

Substances